ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System
01 6월 2024 - 10:00PM
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global
device, cell, and gene therapy-enabling company offering precise
navigation to the brain and spine, today announces full market
release of its SmartFrame OR platform and ClearPoint Prism Neuro
Laser Therapy System at the 2024 Biennial Meeting of the American
Society of Stereotactic and Functional Neurosurgery from Saturday,
June 1st – Tuesday, June 4th in Nashville.
“Deep Brain Stimulation (DBS) has been proven to be a safe and
effective strategy to manage patients with medically intractable
Parkinson’s Disease, Essential Tremor, and Dystonia,1” said Dr. Kim
Burchiel, Professor of Neurological Surgery at the Oregon Health
& Science University. “In its more than 30-year history in the
US, this highly effective therapy has been mostly performed in
highly specialized neurosurgical centers, which, because of their
relative rarity, has resulted in only about 5% of eligible patients
being treated.1 The development of the SmartFrame OR is anticipated
to be a significant step towards accomplishing the triple aim of
achieving excellent outcomes in an accessible and appropriate
clinical setting, with broad patient acceptance, because it is
expected to allow DBS procedures to be performed in a much larger
spectrum of hospitals, by a larger contingent of well-trained
neurosurgeons.”
“ClearPoint Neuro’s new SmartFrame OR solution supports
stereotactic precision packaged in an efficient, intuitive, and
reliable platform,” stated Dr. Andrew Conner, Assistant Professor
of Neurosurgery at Oklahoma University. “It has completely changed
my DBS practice for the better since its release.”
“This is a truly exciting milestone for ClearPoint, and one that
has been years in the making,” commented Joe Burnett, President and
CEO at ClearPoint Neuro. “We set out to prove that we are one of
the most innovative and focused companies in the Neurosurgery
space. We are now walking into the premier stereotactic
neurosurgical conference able to demonstrate new laser therapy, new
operating room navigation, new brain modeling software, new access
products and new drug delivery preclinical and clinical trial
services. This is meaningful innovation that will ultimately
benefit our surgical customers and most importantly, many new
patients around the world.”
At ASSFN, the SmartFrame OR and ClearPoint Prism Neuro Laser
Therapy System will be showcased at:
- Special Course 1: Epilepsy Surgery
Fundamentals and Challenges on Saturday, June 1st
- Special Course 2: Movement Disorder
Surgery Fundamentals and Challenges on Saturday, June 1st
- Meet the Expert Session: Initial
Experience with the SmartFrame OR Platform
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling
company offering precise navigation to the brain and spine. The
Company uniquely provides both established clinical products as
well as pre-clinical development services for controlled drug and
device delivery. The Company’s flagship product, the ClearPoint
Neuro Navigation System, has FDA clearance and is CE-marked.
ClearPoint Neuro is engaged with healthcare and research centers in
North America, Europe, Asia, and South America. The Company is also
partnered with the most innovative pharmaceutical/biotech
companies, academic centers, and contract research organizations,
providing solutions for direct CNS delivery of therapeutics in
pre-clinical studies and clinical trials worldwide. To date,
thousands of procedures have been performed and supported by the
Company’s field-based clinical specialist team, which offers
support and services to our customers and partners worldwide. For
more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the context of the federal securities laws, which
may include the Company’s expectations for the future performance,
market, and revenue of its products and services. These
forward-looking statements are based on management’s current
expectations and are subject to the risks inherent in the business,
which may cause the Company's actual results to differ materially
from those expressed in or implied by forward-looking statements.
Particular uncertainties and risks include those relating to:
global and political instability, supply chain disruptions, labor
shortages, and macroeconomic and inflationary conditions; future
revenue from sales of the Company’s products and services; the
Company’s ability to market, commercialize and achieve broader
market acceptance for new products and services offered by the
Company; the ability of our biologics and drug delivery partners to
achieve commercial success, including their use of the Company’s
products and services in their delivery of therapies; the Company’s
expectations, projections and estimates regarding expenses, future
revenue, capital requirements, and the availability of and the need
for additional financing; the Company’s ability to obtain
additional funding to support its research and development
programs; the ability of the Company to manage the growth of its
business; the Company’s ability to attract and retain its key
employees; and risks inherent in the research, development, and
regulatory approval of new products. More detailed information on
these and additional factors that could affect the Company’s actual
results are described in the “Risk Factors” section of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, and the Company’s Quarterly Report on Form 10-Q for the
three months ended March 31, 2024, both of which have been filed
with the Securities and Exchange Commission. The Company does not
assume any obligation to update these forward-looking
statements.
1 Data on file at ClearPoint Neuro
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef08f4c6-fb7a-4470-b834-6589a0a3adfd
A video accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/dc00d91c-8a9a-410b-a41a-c435136a10b5
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
ClearPoint Neuro (NASDAQ:CLPT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
ClearPoint Neuro (NASDAQ:CLPT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024